New drug delivery - Enhanced stability & bioavailability of poorly soluble APIs

DATE

June 16, 2021

TIME

8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST Duration: 60 Minutes

Overview

Imagine what you could do if working with poorly soluble (BCS2) compounds was not an insurmountable issue. BCS2 compounds account for 40% of the APIs on the market today, however, 70-80% of pharmaceuticals active in the pipeline have been shelved due to solubility issues.

Grace experts will detail new ways silica drug delivery technology is giving pharmaceutical manufacturers a new drug delivery option to improve solubility and bioavailability by improving the physical and chemical stability in pharmaceutical APIs.

Brought to you by:

Speakers

Chintan Shah
Lead Manager, Technical and Customer Service (TCS),
Pharma and Nutrition,
W. R. Grace & Co.

Jeff Huber
Technical Contributing Editor,
C&EN Media Group

Registration

Forwarded this event? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title*

Address 1*

City*

State

Zip / Post Code*

Country*

Business Phone*

Are you working with poorly soluble compounds?*

Do you have API stability challenges? *

Are you looking for innovative approaches to increase the bioavailability of poorly soluble APIs?*

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy.

View On Demand Webinars